Viewing nowCombinationLidoneur-DS Tablet (Risedronate Sodium, Cholecalciferol)
Risedronate Sodium 2.5 Hydrate 172.1mg · Cholecalciferol 0.75mg
Tablet · Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.

MFDS item code 201202525 · Approved 2012.04.03 · Insurance code 643506260
Treatment and prevention of osteoporosis in postmenopausal women
This medication is used to treat and prevent osteoporosis that can occur in postmenopausal women. Osteoporosis is a condition characterized by weakened bone strength, leading to an increased risk of fractures, which is particularly common in postmenopausal women. Regular use of this medication can help increase bone density and reduce the risk of fractures. Therefore, it plays an important role in maintaining healthy bones in postmenopausal women.
1. Adults: Take 1 tablet of this drug orally once a month. 2. Older adults: No dose adjustment is necessary because the bioavailability and pharmacokinetics of this drug in older adults (60 years and older) are similar to those in younger people. 4. Patients with renal impairment: No dose adjustment is necessary for patients with creatinine clearance of 30ml/min or higher. This drug is contraindicated in patients with severe renal impairment and creatinine clearance below 30ml/min. Food interferes with absorption of this drug; for adequate absorption, take it at least 30 minutes before consuming the first food or beverage other than water of the day. To help this drug reach the stomach easily and reduce the possibility of esophageal irritation, take it in an upright position with a sufficient amount of plain water (170 ~ 230mL). Taking it with other beverages, including mineral water, may reduce absorption. Do not chew or suck this drug because of the possibility of oropharyngeal ulceration. Patients should not lie down for at least 30 minutes after taking it. Patients should take supplements if their dietary intake of calcium and vitamin D is inadequate. Patients at high risk of vitamin D deficiency (e.g., patients over 70 years of age, residents of nursing homes, and patients with chronic diseases) may require additional vitamin D supplements. Patients with gastrointestinal malabsorption syndrome may require higher doses of vitamin D supplements, and measurement of 25-hydroxyvitamin D concentrations should be considered. The recommended daily intake of vitamin D is 400IU to 800IU. One monthly dose of this drug provides a month's supply of vitamin D at 1000IU daily. If a patient forgets to take this drug on the scheduled day, follow these instructions: - If the next scheduled dose is at least 7 days away, take 1 tablet the next morning after remembering. Take the next dose on the originally scheduled day. Do not take more than 1 tablet of this drug within 7 days. - If the next scheduled dose is within 7 days, wait until the originally scheduled day and then take 1 tablet of this drug.
3. Children: Safety and efficacy have not been established in children and adolescents who are still growing.
This medication can irritate the mucous membranes of the stomach and esophagus, potentially leading to problems such as esophagitis or esophageal ulcers. It is important to take it with a sufficient amount of water and to avoid lying down for a period of time after taking it. If symptoms such as difficulty swallowing or heartburn occur during treatment, it should be discontinued immediately and a doctor should be consulted. Patients with esophageal disorders or upper gastrointestinal conditions such as gastritis or duodenitis should use this medication with caution. Patients with esophageal motility disorders or hypocalcemia, severe kidney disease, and pregnant or breastfeeding women should not take this medication. When taking this medication, ensure sufficient intake of calcium and vitamin D, and if deficient, consider taking supplements. Antacids or supplements containing divalent cations such as calcium, magnesium, or iron can interfere with the absorption of this medication and should not be taken together. In cases of dental surgery or oral infections, there may be a risk of osteonecrosis of the jaw, so it is essential to consult a doctor before treatment. This medication has not been established as safe and effective for children, so it is advisable not to use it in pediatric patients. In case of overdose, blood calcium levels may drop, so symptoms should be reported to healthcare professionals immediately for appropriate treatment. If any unusual symptoms occur during treatment, consult a doctor immediately and follow the prescribed dosing regimen carefully.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air and moisture from entering, and it is recommended to store it at room temperature between 1°C and 30°C. Storing it this way can help maintain the medication's effectiveness for a longer time.
Blue oval film-coated tablet
1 tablet/box [1 tablet/PTP x 1]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationRisedronate Sodium 2.5 Hydrate 172.1mg · Cholecalciferol 0.75mg
Tablet · Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationRisedronate Sodium 2.5 Hydrate 172.1mg · Cholecalciferol 0.75mg
Tablet · Prescription medication · Combination
Hanlim Pharmaceutical Co., Ltd.
CombinationRisedronate Sodium 2.5 Hydrate 172.1mg · Cholecalciferol 0.75mg
Tablet · Prescription medication · Combination
DongKook Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.